Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 with chemotherapy ± anlotinib in advanced endometrial cancer and uterine sarcoma
NCT05481645Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2022
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in endometrial cancer (EC), uterine sarcoma, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Aug 2022; status: terminated.
02
Drugs
benmelstobart
03
Conditions
endometrial cancer (EC)uterine sarcoma
Beyond the preview
Go deeper on NCT05481645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481645.